Gemcitabine in the treatment of bladder cancer

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 3, 2000, Pages 547-553

  Ryan, Christopher W ^a   Vogelzang, Nicholas J ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Antimetabolites; Bladder cancer; Cisplatin; Clinical trials; Gemcitabine; Transitional cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CISPLATIN; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE;

BLADDER TUMOR; HUMAN; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 0034158324     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.3.547     Document Type: Review

References (31)

1. LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer Statistics, 1999. CA Cancer J. Clin. (1999) 49:8-31.
2. STERNBERG CN, YAGODA A, SCHER HI et al.: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (1989) 64:2448-2458. Updated Phase II data on 133 patients treated at Memorial Sloan-Kettering Cancer Center with the M-VAC regimen.
3. LOEHRER PJ, EINHORN LH, ELSON PJ et al.: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxonibicin in patients with metastatic urothelial carcinoma: a co-operative group study. J. Clin. Oncol. (1992) 10:1066-1073. Randomised trial that demonstrated M-VAC to be superior to single-agent cisplatin with respect to response rate, duration of remission and overall survival.
4. LOGOTHETIS CJ, DEXEUS FH, FINN L et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. (1990) 8:1050-1055. Randomised trial that established M-VAC as superior to the combination chemotherapy CISCA regimen in terms of both response rate and survival.
5. HARKER WG, MEYERS FJ, FREIHA FS et al.: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J. Clin. Oncol. (1985) 3:1463-70.
6. SAXMAN SB, PROPERT KJ, EINHORN LH et al.: Long-term follow-up of a Phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. (1997) 15:2564-2569. Long-term results of randomised trial that confirm improved survival with M-VAC in comparison to single-agent cisplatin.
7. HERTEL LW, BODER GD, KROIN JS, RINZEL SM, POORE GA, TODD GC: Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. (1990) 50:4417-4422.
8. ABBRUZZESE JL, GRUNEWALD R, WEEKS EA et al.: A Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. (1991) 9:491-498.
9. GREEN MR: Gemcitabine: safety overview. Semin. Oncol. (1996) 23(Suppl. 10):32-35.
10. NELSON R, TARASSOFF P: Dyspnoea with gemcitabine is commonly seen, often disease related, transient and rarely severe. Eur. J. Cancer (1998) 31(Suppl. 5):S197-S198.
11. BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15:2403-2413.
12. LE CHEVALIER T: Single agent activity of gemcitabine in advanced non-small cell lung cancer. Semin. Oncol. (1996) 23(Suppl. 10):36-42.
13. CARMICHAEL J, POSSINGER K, PHILLIP P et al.: Advanced breast cancer: a Phase II trial with gemcitabine. J. Clin. Oncol. (1995) 13:2731-2736.
14. LUND B, HANSEN OP, THEILADE K et al.: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J. Natl. Cancer Inst. (1994) 86:1530-1533.
15. POLLERA CF, CERIBELLI A, CRECCO M, CALABRESI F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a Phase I study. Ann. Oncol. (1994) 5:182-184.
16. LORUSSO V, POLLERA CF, ANTIMI M et al.: A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer (1998) 34:1208-1212.
17. MOORE MJ, TANNOCK IF, ERNST S, HUAN S, MURRAY N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J. Clin. Oncol. (1997) 15:3441-3445. Results of a Phase II trial that demonstrated single-agent activity of gemcitabine in bladder cancer.
18. STADLER WM, KUZEL T, ROTH B, RAGHAVAN D, DORR FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J. Clin. Oncol. (1997) 15:3394-3398. Additional Phase II study of single-agent gemcitabine in bladder cancer that established activity in this disease
19. PETERS GJ, RUIZ VAN HAPEREN VWT, BERGMAN AM et al.: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin. Oncol. (1996) 23:16-24.
20. VON DER MAASE H, ANDERSEN L, CRINO L, WEISSBACH L, DOGLIOTTI L: A Phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc. Am. Soc. Clin. Oncol. (1997) 16:A1155.
21. KAUFMAN D, STADLER WM, CARDUCCI M et al.: Gemcitabine (Gem) plus cisplatin (CDOP) in metastatic transitional cell carcinoma (TCC): final results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (1998) 17:320A.
22. MOORE MJ, WINQUIST EW, MURRAY N et al.: Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a Phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (1999) 17:2876-2881. Phase II study of gemcitabine plus cisplatin in bladder cancer that showed significant activity.
23. ROTH B, DREICER R, EINHORN LH et al.: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a Phase II trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. (1994) 12:2264-2270. Phase II study that demonstrated significant activity of single-agent paclitaxel in bladder cancer.
24. MCCAFFREY JA, HILTON S, MAZUMDAR M et al.: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J. Clin. Oncol. (1997) 15:1853-1857.
25. ROTHENBERG ML, SHARMA A, WEISS GR et al.: Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann. Oncol. (1998) 9:733-738.
26. MARINI L, STERNBERG CN, SELLA A, CALEBRÒ F, VAN RIJN A: A new regimen of gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma. Proc. Am. Soc. Clin. Oncol. (1999) 18:346a. Abstract 1335.
27. VAISHAMPAYAN U, SMITH D, REDMAN B, KUCUK O, ENSLEY J, HUSSAIN M: Phase II evaluation of carboplatin, paclitaxel and gemcitabine in advanced urothclial carcinoma. Proc. Am. Soc. Clin. Oncol. (1998) 18:333a. Abstract 1282.
28. DODD PM, MCCAFFREY JA, HILTON S et al.: Phase I evaluation of sequential doxorubicin + gemcitabine (AG) then ifosfamide + paclitaxel + cisplatin (TIP) for patients (pts) with unresectable or metastatic transitional cell carcinoma (TCC). Proc. Am. Soc. Clin. Oncol. (1999) 18:330a. Abstract 1268.
29. BAJORIN DF, DODD PM, MAZUMDAR M et al.: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. (1999) 17:3173-3181.
30. COZZI PJ, BAJORIN DF, TONG W et al.: Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin. Cancer Res. (1999) 5:2629-2637.
31. 2) levels. Invest. New Drugs (1997) 15:115-121.